4DMedical Ltd (ASX:4DX) has delivered one of the clearest validation points yet for its flagship lung imaging technology, securing a deployment at the Mayo Clinic — widely regarded as the top-ranked hospital system in the United States.
The market reaction was immediate and emphatic. Shares in the ASX-listed company surged as much as 38% in Wednesday trading and were up about 35% at 3:30 pm AEDT, extending a five-day rally of more than 60% as investors responded to what is being seen as a defining commercial and clinical milestone.
A reference site that matters
Under the agreement, Mayo Clinic will deploy 4DMedical’s CT:VQ technology over an initial 90-day period, integrating it into clinical workflows and assessing its use across a range of pulmonary and cardiothoracic applications.
The rollout starts as a trial deployment, but the real significance lies in what could follow if it converts into a full commercial relationship.
Mayo is not just another hospital customer — it is an institution that influences clinical guidelines, physician behaviour and procurement decisions across the US and beyond. Its adoption sends a strong signal that CT:VQ is not only technically viable, but clinically relevant in real-world settings.
That signal builds on a growing list of high-profile deployments. Since securing FDA clearance in September 2025, 4DMedical has now placed CT:VQ at six leading US academic medical centres, including Stanford, Cleveland Clinic and UC San Diego Health.
Reaching that level of penetration in roughly seven months points to unusually fast early traction for a new imaging modality — particularly in a conservative healthcare system where adoption cycles are typically long and evidence-driven.
Why CT:VQ is gaining traction
CT:VQ is designed to provide combined ventilation and perfusion analysis using standard CT scans, offering a functional view of lung performance without the need for nuclear medicine or contrast agents.
That matters for a few reasons:
- It simplifies workflow by integrating into existing CT infrastructure
- It avoids radioisotopes, which can be costly and logistically complex
- It offers higher-resolution imaging compared with traditional nuclear techniques
- It aligns with established reimbursement pathways
Together, those factors help address one of the biggest barriers in medtech adoption: not just proving clinical benefit, but fitting seamlessly into how hospitals already operate.
The company is also leaning into a “reference site” strategy — targeting elite institutions first, then using those deployments to drive broader uptake. Mayo’s inclusion significantly strengthens that network.
Momentum building beyond a single deal
This latest deployment does not stand in isolation. It sits alongside a broader commercial push that has been gathering pace over the past year.
Recent developments have included:
- A growing order pipeline supported by an expanded partnership with Philips
- Earlier deployments at major US academic centres such as UC San Diego Health
- Continued expansion of its SaaS-based imaging platform and AI capabilities
These steps suggest 4DMedical is moving beyond proof-of-concept and into early commercial scaling — albeit still in the validation-heavy phase typical of healthcare technologies.
The key question now is conversion: how many of these initial deployments translate into long-term, revenue-generating contracts?
Market reaction reflects a shift in perception
The sharp share price move suggests investors are starting to price in that possibility.
While the Mayo agreement itself does not materially change near-term earnings forecasts, it shifts the narrative around execution risk. Securing one of the most influential healthcare institutions in the world reduces uncertainty around clinical acceptance — a major hurdle for any new diagnostic technology.
It also reinforces the idea that CT:VQ could evolve from a niche innovation into a broader standard of care in lung imaging, particularly if further deployments follow and clinical data continues to build.
For now, the story remains in its early commercial phase. But with six top-tier US hospitals now on board in under a year, 4DMedical has moved into a different category — one where the conversation is no longer about whether the technology works, but how far and how fast it can scale.